1. Home
  2. LZM vs MNPR Comparison

LZM vs MNPR Comparison

Compare LZM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifezone Metals Limited

LZM

Lifezone Metals Limited

N/A

Current Price

$4.43

Market Cap

385.4M

ML Signal

N/A

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$56.70

Market Cap

372.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LZM
MNPR
Founded
2021
2014
Country
Isle of Man
United States
Employees
142
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
385.4M
372.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LZM
MNPR
Price
$4.43
$56.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
13
Target Price
$7.00
$101.42
AVG Volume (30 Days)
193.9K
150.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$510.94
N/A
Revenue Next Year
$217.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.90
$26.06
52 Week High
$6.23
$105.00

Technical Indicators

Market Signals
Indicator
LZM
MNPR
Relative Strength Index (RSI) 45.85 47.26
Support Level $4.13 $56.15
Resistance Level $4.42 $61.30
Average True Range (ATR) 0.26 3.32
MACD 0.02 0.79
Stochastic Oscillator 51.33 60.22

Price Performance

Historical Comparison
LZM
MNPR

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: